Laekna, Inc. 2105

HKEX · Hong Kong SAR China · Health Technology

HKD 8.76+0.49 (+5.99%)

Market closed· Oct 2, 2026, 7:56 AM UTC· HKD · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

Laekna, Inc. 2105

HKEX · Hong Kong SAR China · Health Technology

HKD 8.76+0.49 (+5.99%)

Market closed· Oct 2, 2026, 7:56 AM UTC· HKD · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

-47.48% · 6MFull-screen chart

Open HKD 8.30High HKD 8.81Low HKD 7.45Close HKD 8.76Volume 2.86M

Oct 2, 2026

Charts by TradingView Lightweight Charts

Key statistics

Previous close: HKD 8.27
Day range: HKD 7.45 – HKD 8.81
52-week range: HKD 5.37 – HKD 19.36
Volume: 2.86M
Market cap: HKD 3.51B
Next earnings date: 2027-03-30
Avg. volume (1Y): 2.59M

Performance

1 week

+27.25%

1 month

+34.15%

3 months

+18.33%

6 months

-53.02%

Year to date

-35.39%

1 year

-47.43%

Total return, dividends included.

Company profile

Sector: Health Technology
Industry: Biotechnology
Country: Hong Kong SAR China
Exchange: HKEX
Shares outstanding: 418.97M
Employees: 83
ISIN: KYG5340S1093
Beta: 1.14

Technical view

Mixed

Where the price sits against its 50- and 200-day moving averages.

Valuation & analysis

Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.

News

Yahoo FinanceAug 12, 2026

New Drug Application for LAE002 (afuresertib) Accepted by China's National Medical Products Administration

Laekna (2105.HK) announced today that the New Drug Application (NDA) for LAE002 (afuresertib) has been accepted by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) for the treatment of patients with locally advanced or metastatic HR+/HER2- breast cancer (LA/mBC) with PIK3CA/AKT1/PTEN alterations, following recurrence or progression on or after endocrine therapy(-ies) (with or without a CDK4/6 inhibitor).

Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.